Xencor Inc Uncategorized Contracts & Agreements
8 Contracts & Agreements
- Amended and Rest (Filed With SEC on February 29, 2024)
- Amendment to the Cross-License Agreement, dated January 2, 2020, by and between the Company and MedImmune, LLC (Filed With SEC on February 24, 2021)
- CROSS-LICENSE AGREEMENT (Filed With SEC on November 4, 2013)
- Xencor, Inc.111 West Lemon AvenueMonrovia, CA 91016Attn: Bassil Dahiyat, CEOFax: +1 ###-###-#### Copy: Morisson & forester LLP (Filed With SEC on October 25, 2013)
- GPEx-DERIVED CELL LINE SALE AGREEMENT by and between Catalent Pharma Solutions LLC and Xencor, Inc. (Filed With SEC on October 25, 2013)
- Xencor, Inc.111 West Lemon AvenueMonrovia, CA 91016Attn: Bassil Dahiyat, CEOFax: +1 ###-###-#### Copy: Morisson & forester LLP (Filed With SEC on October 11, 2013)
- GPEx-DERIVED CELL LINE SALE AGREEMENT by and between Catalent Pharma Solutions LLC and Xencor, Inc. (Filed With SEC on October 11, 2013)
- INDEMNITY AGREEMENT (Filed With SEC on October 11, 2013)
